Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 796

Sort by

Sort Order Select

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Julie Kanter, MD, Mary Dooley, MS, Logan P Sirline, MPH, Martina Mueller, PhD, Shannon Phillips, PhD RN, Alyssa M Schlenz, PhD, Cathy Melvin, PhD MPH, Robert J. Adams, MD MS

Blood (2019) 134 (Supplement_1): 2270.

https://doi.org/10.1182/blood-2019-129951

Published: 2019

Journal Articles

Preclinical Evaluation of ALS20, a New and Improved Lentiviral Vector for Beta-Globinopathies

Laura Breda, PhD, Valentina Ghiaccio, PhD, Silvia Pires Lourenco, MSc, Danuta Jadwiga Jarocha, PhD, Yasuhiro Ikawa, MD PhD, Naoto Tanaka, PhD, Virginia Guzikowski, Carla Casu, PhD, Kim Smith-Whitley, MD, Janet L. Kwiatkowski, MD MSCE, Stefano Rivella, PhD

Blood (2019) 134 (Supplement_1): 2242.

https://doi.org/10.1182/blood-2019-124043

Published: 2019

Journal Articles

A Novel Method for Flow Cytometric Quantification of Human Platelet Membrane Glycoproteins in Citrated Whole Blood

Christina Berens, MD, Jens Müller, Heiko Rühl, MD, Johannes Oldenburg, Bernd Pötzsch, MD

Blood (2019) 134 (Supplement_1): 2367.

https://doi.org/10.1182/blood-2019-124646

Published: 2019

Journal Articles

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Afshin Ameri, MD, Meera B. Chitlur, MD, Marcio A. Almeida, PhD, Karin Haack, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, M.B.A., M.P.H., Jerry S. Powell, MD, Miguel A. Escobar, MD, Raja Rajalingam, PhD, Sarah Williams-Blangero, PhD, Carol K. Kasper, MD, Laura Almasy, PhD, Shelley Cole, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2019) 134 (Supplement_1): 2393.

https://doi.org/10.1182/blood-2019-132218

Published: 2019

Journal Articles

Oral Adherence in Adults with Acute Myeloid Leukemia: Results of a Mixed Methods Study

Ashley Leak Bryant, PhD RN, Thomas W. LeBlanc, MDMA,MHS, Tara Albrecht, PhDANP, Ya-Ning Chan, Jaime Richardson, Matthew C Foster, MD, Dang Malisa, Susie Owenby, Debra Wujcik, PhD

Blood (2019) 134 (Supplement_1): 2215.

https://doi.org/10.1182/blood-2019-130514

Published: 2019

Journal Articles

An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)

DR. Brian Koffman, John M. Pagel, MD PhD DSc, Andy Kaempf, Byung Park, PhD, Liza Avruch, Christopher Lee, PhD MS, Babak Movassaghi, PhD MBA, John C. Byrd, MD, Alan Skarbnik, MD, Matthew S. Davids, MD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4716.

https://doi.org/10.1182/blood-2019-123579

Published: 2019

Journal Articles

Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC)

Blood (2019) 134 (Supplement_1): 2700.

https://doi.org/10.1182/blood-2019-127475

Published: 2019

Journal Articles

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Sunisa Kongkiatkamon, Anand Tiwari, Vera Adema, PhD, Cassandra M Kerr, MS, Bartlomiej Przychodzen, Hassan Awada, Jibran Durrani, Yvonne Parker, Drew Adams, Yuriy Fedorov, Hetty E. Carraway, MD MBA, Chao-Yie Yang, Mikkael A. Sekeres, MD MS, Daniel J. Lindner, James G Phillips, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 881.

https://doi.org/10.1182/blood-2019-128671

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 751.

https://doi.org/10.1182/blood-2019-129323

Published: 2019

Journal Articles

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Blood (2019) 134 (Supplement_1): 830.

https://doi.org/10.1182/blood-2019-131494

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Bach1 Inhibitors Reduce Stasis in Townes Sickle Cell Mouse Model

John D Belcher, PhD, Margaret Biddle, PhD, Domi Stickens, PhD, Lyndsay Olson, Eric Bell, Chunsheng Chen, Fuad Abdulla, Julia Nguyen, Zachary Monroe Kiser, BS, PhD, Jacob Lloyd, MD, Gregory M Vercellotti, MD

Blood (2019) 134 (Supplement_1): 983.

https://doi.org/10.1182/blood-2019-127300

Published: 2019

Journal Articles

Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)

Binod Dhakal, MBBS, Raphael Fraser, PhD, Zhubin Gahvari, MD, Aric C. Hall, MD, Natalie Scott Callander, MD, Saurabh Chhabra, MD, Omar Davila, Shaji K. Kumar, MD, Nina D. Shah, MD, Muzaffar H. Qazilbash, MD, Anita D'Souza, MDMS, Parameswaran Hari, MBBS, MD

Blood (2019) 134 (Supplement_1): 783.

https://doi.org/10.1182/blood-2019-126646

Published: 2019

Journal Articles

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Jeanne Mendell, PhD MPH, Ruth Namuyinga, MD MPH, Hoang Pham, PharmD, Nabil Said, MD MPH, Yibin Wang, PhD, Tsvetomir Mitov, MD, Ben Kim, PharmD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 1372.

https://doi.org/10.1182/blood-2019-121762

Published: 2019

Journal Articles

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Blood (2019) 134 (Supplement_1): 1527.

https://doi.org/10.1182/blood-2019-126889

Published: 2019

Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 1344.

https://doi.org/10.1182/blood-2019-122097

Published: 2019

Journal Articles

Treatment‐Related Acute Myeloid Leukemia in Children

Katharina Waack, Katharina Röllecke, PhD, Mareike Rasche, MD, Christiane Walter, MSc, Ursula Creutzig, MD PhD, Dirk Reinhardt, MD PhD

Blood (2019) 134 (Supplement_1): 1322.

https://doi.org/10.1182/blood-2019-131911

Published: 2019

Journal Articles

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Blood (2019) 134 (Supplement_1): 1358.

https://doi.org/10.1182/blood-2019-125262

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Preclinical Evaluation of ALS20, a New and Improved Lentiviral Vector for Beta-Globinopathies

A Novel Method for Flow Cytometric Quantification of Human Platelet Membrane Glycoproteins in Citrated Whole Blood

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Oral Adherence in Adults with Acute Myeloid Leukemia: Results of a Mixed Methods Study

An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)

Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC)

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Bach1 Inhibitors Reduce Stasis in Townes Sickle Cell Mouse Model

Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Treatment‐Related Acute Myeloid Leukemia in Children

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only